Comparative Pharmacology
Head-to-head clinical analysis: ALPHADERM versus FLUOCINONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHADERM versus FLUOCINONIDE.
ALPHADERM vs FLUOCINONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
Fluocinonide is a potent corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced prostaglandin and leukotriene synthesis. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.
Topical: Apply a thin film to affected area 1-3 times daily. Limitation of use: Should not exceed 60 g per week in adults.
None Documented
None Documented
Clinical Note
moderateFluocinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Gatifloxacin."
Clinical Note
moderateFluocinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Rosoxacin."
Clinical Note
moderateFluocinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life is approximately 1.3-2.4 hours in plasma. Clinically, due to high tissue binding and slow release from skin, the pharmacodynamic half-life for topical effect may extend to 12-24 hours.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; less than 10% metabolized hepatically.
Primarily hepatic metabolism; inactive metabolites excreted renally and fecally. Renal elimination accounts for approximately 60-70% of total clearance, fecal elimination ~30-40%. Less than 1% excreted unchanged in urine.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid
Fluocinonide + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Trovafloxacin."